Document:

EXHIBIT
10.3

 

AMENDMENT
NO. 2 TO WARRANT TO PURCHASE STOCK

 

This
Amendment No. 2 to Warrant to Purchase Stock (this “Amendment”), dated as of December 27, 2016, is being entered
into between Imprimis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and IMMY Funding LLC,
a Delaware limited liability company (“IMMY Funding”). Capitalized terms used in this Amendment without definition
have the respective definitions ascribed to them in the Existing Warrant (as defined below).

 

WHEREAS,
the Company and IMMY Funding have agreed to amend that certain Warrant to Purchase Stock, dated as of May 11, 2015, between the
Company and IMMY Funding (the “Original Warrant”), as amended by that certain Amendment to Warrant to Purchase
Stock, dated as of January 22, 2016, between the Company and IMMY Funding (the Original Warrant, as so amended, the “Existing
Warrant”), in the manner provided in this Amendment (the Existing Warrant, as amended by this Amendment, the “Warrant”).

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:

 

Section
1.Amendments to Warrant.

 

Effective
as of the execution and delivery of this Amendment, the Warrant Price will be $1.79 per share of common stock, $0.001 par value
per share, of the Company. For the avoidance of doubt, the Warrant Price will be subject to further adjustment as provided in
the Warrant.

 

Section
2.Miscellaneous.

 

(A)       Generally.
Sections 5.7, 5.8, 5.9 and 5.10 of the Original Warrant will apply to this Amendment as if the same were reproduced in this Amendment,
mutatis mutandis.

 

(B)       Affirmation
of Warrant. The parties hereby affirm all provisions of the Existing Warrant as amended by this Amendment.

 

[Remainder
of Page Intentionally Left Blank; Signature Page Follows]

 

    	 	- 1 - 	 

    	 

    

 

The
parties hereto have executed this Amendment as of the date first written above.

 

	 	Imprimis
    Pharmaceuticals, Inc.
	 	 	 
	 	By:	/s/
    Andrew R. Boll
	 	Name:	Andrew
    R. Boll
	 	Title:	CFO
    and Secretary
	 	 	 
	 	IMMY
    Funding LLC
	 	 	 
	 	By:	/s/
    Stephen J. DeNelsky
	 	Name:	Stephen
    J. DeNelsky
	 	Title:	President

 

    	[Signature Page to Amendment to Warrant to Purchase Stock]Exhibit 4.1

 

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE
SECURITIES ACT, OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY
SATISFACTORY TO THE COMPANY.

 

PARETEUM CORPORATION

 

WARRANT TO PURCHASE COMMON STOCK

 

	Warrant No. 1	Original Issue Date: December 27, 2016

 

Pareteum Corporation, a Delaware corporation
(the “Company”), hereby certifies that, for value received, Corbin Mezzanine Fund I, L.P. or its permitted registered
assigns (the “Holder”), is entitled to purchase from the Company up to a total of 27,051,627 shares of common
stock, $0.00001 par value per share (the “Common Stock”), subject to adjustment as provided in Section 9
herein, of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”)
at an exercise price per share equal to $0.13 per share (as adjusted from time to time as provided in Section 9 herein,
the “Exercise Price”), at any time and from time to time on or after the date hereof (the “Issue Date”)
and through and including 5:30 P.M., New York time, on December 27, 2019 (the “Expiration Date”), and subject
to the following terms and conditions:

 

This Warrant (this “Warrant”)
is one of one or more Warrants (together with any New Warrants outstanding from time to time as contemplated by Section 3
herein, the “Warrants”) issued pursuant to that certain Amended and Restated Credit Agreement, dated as of December
27, 2016 by and among the Company, the other Credit Parties identified therein, Atalaya Administrative LLC, as administrative agent
and collateral agent, and the Lenders identified therein, as amended from time to time (the “Credit Facility”).

 

1.             Definitions.
In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings
given to such terms in the Credit Facility.

 

2.             Registration
of Warrant. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered
assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.

 

     

     

    

  

3.             Registration
of Transfers. Subject to compliance with all applicable securities laws, the Company shall register the transfer of all or
any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached as Schedule
2 hereto duly completed and signed, to the Company’s transfer agent or to the Company at its address specified in the
Credit Facility and (x) delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory to the Company
to the effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from the registration
requirements of the Securities Act and all applicable state securities or blue sky laws and (y) delivery by the transferee of
a written statement to the Company (i) certifying that the transferee is an “accredited investor” as defined in Rule
501(a) under the Securities Act and (ii) representing to the Company that the transferee is purchasing the Warrant (or a portion
thereof) for its own account and not with a view toward a distribution within the meaning of the Securities Act, to the Company
at its address specified in the Credit Facility. Notwithstanding the foregoing, no opinion of counsel shall be required in the
case of a transfer by a registered Holder to an Affiliate of such Holder. Upon any such registration or transfer, a new warrant
to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a “New Warrant”)
evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining
portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant
by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of
the New Warrant that the Holder has in respect of this Warrant. The Company shall prepare, issue and deliver at its own expense
any New Warrant under this Section 3.

 

4.             Exercise
and Duration of Warrant.

 

(a)          Subject
to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 11), all or any
part of this Warrant shall be exercisable by the registered Holder in any manner permitted by Section 10 of this Warrant
at any time and from time to time on or after the Issue Date and through and including 5:30 P.M. New York time, on the Expiration
Date. At 5:30 P.M., New York time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and
become void and of no value and this Warrant shall be terminated and no longer outstanding.

 

(b)          The
Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1
hereto (the “Exercise Notice”), completed and duly signed, and (ii) payment of the Exercise Price for the number
of Warrant Shares as to which this Warrant is being exercised (which may take the form of a “cashless exercise” if
so indicated in the Exercise Notice and if a “cashless exercise” may occur at such time pursuant to Section 10
below), and the date such items are delivered to the Company (as determined in accordance with the notice provisions hereof) is
an “Exercise Date.” The Holder shall not be required to deliver the original Warrant in order to effect an exercise
hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and
issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.

 

    	 	2	 

     

    

  

(c)          Notwithstanding
the foregoing, the Company shall not issue any shares of Common Stock pursuant to the terms of this Warrant if the issuance of
such shares of Common Stock would exceed the aggregate number of shares of Common Stock which the Company may issue pursuant to
the terms of this Warrant without breaching the Company’s obligations under the rules or regulations of the NYSE MKT, LLC
(“Principal Trading Market” or “NYSE MKT”) (the number of shares which may be issued without
violating such rules and regulations, the “Exchange Cap”), except that such limitation shall not apply in the
event that the Company obtains the approval of its stockholders as required by the applicable rules of the Principal Trading Market
for issuances of shares of Common Stock in excess of such amount. The Holder acknowledges that under the current rules of NYSE
MKT, stockholders’ approval is required in case of issuance of additional shares in connection with: (i) a transaction involving
(A) the sale, issuance, or potential issuance of Common Stock (or securities convertible into Common Stock) at a price less than
the greater of book or market value which together with sales by officers, directors or principal shareholders of the Company equals
20% or more of then outstanding Common Stock; or (B) the sale, issuance, or potential issuance of Common Stock (or securities convertible
into Common Stock) equal to 20% or more of then outstanding stock for less than the greater of book or market value of the stock;
or (ii) a transaction when the issuance or potential issuance of additional shares will result in a change of control of the issuer.
In the event that (x) the Exercise Price of this Warrant would otherwise be reduced pursuant to Section 9(d) hereof to a
price lower than the greater of book or market value of the Common Stock as of the Original Issue Date (the “Price Limit”),
or (y) the number of shares into which this Warrant may be exercised, taking into account the limitations under Section 11
hereof, would otherwise exceed the Exchange Cap, the Company shall use commercially reasonable efforts to obtain its stockholders’
approval of the adjustment to the Exercise Price or the issuance of shares of Common Stock exceeding the Exchange Cap, as the case
may be, at its next scheduled annual meeting of stockholders, and the Expiration Date of this Warrant shall be the date sixty (60)
days following such annual meeting or the original Expiration Date, whichever is later. Until such approval is obtained, the Exercise
Price shall not be adjusted below the Price Limit and the Holders shall not be issued in the aggregate, pursuant to the terms of
this Warrant, shares of Common Stock in an amount greater than the Exchange Cap, respectively.

 

5.             Delivery
of Warrant Shares.

 

(a)           Upon
exercise of this Warrant, the Company shall promptly (but in no event later than three Trading Days after the Exercise Date) issue
or cause to be issued and cause to be delivered to or upon the written order of the Holder, (i) a certificate for the Warrant Shares
issuable upon such exercise, free of restrictive legends, or (ii) an electronic delivery of the Warrant Shares to the Holder’s
account at the Depository Trust Company (“DTC”) or a similar organization, unless in the case of clause (i)
and (ii) a registration statement covering the resale of the Warrant Shares and naming the Holder as a selling stockholder thereunder
is not then effective or the Warrant Shares are not freely transferable without volume restrictions pursuant to Rule 144 under
the Securities Act, in which case such Holder shall receive a certificate for the Warrant Shares issuable upon such exercise with
appropriate restrictive legends. The Holder, or any Person permissibly so designated by the Holder to receive Warrant Shares, shall
be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date; provided, that the Holder has complied
with the terms of this Warrant governing the exercise of this Warrant. If the Warrant Shares are to be issued free of all restrictive
legends, the Company shall, upon the written request of the Holder, use its reasonable best efforts to deliver, or cause to be
delivered, Warrant Shares hereunder electronically through The Depository Trust Company or another established clearing corporation
performing similar functions, if available; provided, that, the Company may, but will not be required to, change its transfer agent
if its current transfer agent cannot deliver Warrant Shares electronically through such a clearing corporation. For purposes of
this Warrant, a “Trading Day” means any day on which the Common Stock is traded on the NYSE MKT, or, if the
NYSE MKT is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market
on which the Common Stock is then traded; provided, that “Trading Day” shall not include any day on which the
Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day on which the Common Stock is suspended
from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance
the closing time of trading on such exchange or market, then during the hour ending at 4:00 p.m., New York time).

 

    	 	3	 

     

    

  

(b)          If
by the close of the third Trading Day after delivery of a properly completed Exercise Notice and the payment of the aggregate exercise
price in any manner permitted by Section 10 of this Warrant, the Company fails to deliver to the Holder a certificate representing
the required number of Warrant Shares or to credit the Holder’s balance account at DTC for the required number of Warrant
Shares, in each case in the manner required pursuant to Section 5(a), and if after such third Trading Day and prior to the
receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall, within three Trading Days after the Holder’s request and in the Holder’s sole discretion, either
(1) pay in cash to the Holder an amount equal to the Holder’s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased, at which point the Company’s obligation to deliver such certificate (and to
issue such Warrant Shares) shall terminate or (2) promptly honor its obligation to deliver to the Holder a certificate or certificates
representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of the Holder’s total
purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In over the product
of (A) the number of shares of Common Stock purchased in the Buy-In, multiplied by (B) the Closing Sale Price of a share of Common
Stock on the Exercise Date.

 

(c)          To
the extent permitted by law (including the rules of the NYSE MKT or the Company’s principal trading market at the time and
the rules and regulations promulgated by the U.S. Securities and Exchange Commission), the Company’s obligations to issue
and deliver Warrant Shares in accordance with and subject to the terms hereof are absolute and unconditional, irrespective of any
action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery
of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination,
or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged
violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such
obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit the Holder’s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    	 	4	 

     

    

  

6.             Charges,
Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect
of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that
the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of
any certificates for Warrant Shares or the Warrant in a name other than that of the Holder or an Affiliate thereof. The Holder
shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving
Warrant Shares upon exercise hereof.

 

7.             Replacement
of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange
and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon
receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case,
a customary affidavit of loss and an indemnity and surety bond, if requested by the Company or the Company’s transfer agent,
in a form that is reasonably satisfactory to the Company and its transfer agent. Applicants for a New Warrant under such circumstances
shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the
Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver
such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue the New Warrant.

 

8.             Reservation
of Warrant Shares. The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized
but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise
of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise
of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking
into account the adjustments and restrictions of Section 9, and without regard to any limitations on exercise under Section
11). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the
applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable.
The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as
provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated
quotation system upon which the Common Stock may be listed.

 

9.             Certain
Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment
from time to time as set forth in this Section 9.

 

(a)          Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common
Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides
its outstanding shares of Common Stock into a larger number of shares, or (iii) combines its outstanding shares of Common Stock
into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of
which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of
this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately
after the effective date of such subdivision or combination.

 

    	 	5	 

     

    

  

(b)          Pro
Rata Distributions. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock
for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by
the preceding paragraph) or (iii) rights or warrants to subscribe for or purchase any security, or (iv) any other asset (in each
case, “Distributed Property”), then, upon any exercise of this Warrant that occurs after the record date fixed
for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to
the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have
been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares
immediately prior to such record date without regard to any limitation on exercise contained therein.

 

(c)           Number
of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to paragraph (a) of this Section 9,
the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately,
so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares
shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment.

 

(d)          Certain
Rights Offerings. In the event that the Company at any time or from time to time issues or distributes subscription rights,
or fixes a record date for the distribution of subscription rights, whether or not such rights are transferable, to holders of
its Common Stock to purchase shares of capital stock of the Company at a subscription price per share of Common Stock (or, if capital
stock that is convertible into Common Stock is offered pursuant to such subscription rights, at an implied price per share of Common
Stock based upon the subscription price therefor and, if applicable, the price at which such capital stock may be converted or
exchanged into Common Stock and the number of shares of Common Stock into which such capital stock may be converted or exchanged,
or if capital stock that is not convertible into Common Stock is offered, at the implied price per share of Common Stock as the
Board of Directors of the Company may in good faith determine) (such price, the “Subscription Price”) that is
less than the then-applicable Exercise Price as of the close of business on the record date for determining the holders of Common
Stock entitled to receive such distribution (or, if there is no such record date, on the date of such distribution), then in such
case the Exercise Price shall be reduced to equal the Subscription Price, such adjustment to be effective upon the close of business
on such record date (or, if there is no such record date, upon the close of business on the date of such distribution); provided,
that an adjustment shall be made only once under this Section 9(d), after which no adjustment shall be made for subsequent rights
offerings or similar transactions; and provided, further, that in no event shall the Exercise Price be increased
hereunder.

 

    	 	6	 

     

    

  

(e)           Fundamental
Transactions. If, at any time while this Warrant is outstanding (i) the Company effects (A) any merger of the Company
with (but not into) another Person, in which stockholders of the Company immediately prior to such transaction own less than a
majority of the outstanding stock of the surviving entity, or (B) any merger or consolidation of the Company into another Person,
(ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any
tender offer or exchange offer approved or authorized by the Company’s Board of Directors is completed pursuant to which
holders of at least a majority of the outstanding Common Stock tender or exchange their shares for other securities, cash or property,
or (iv) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision
or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”),
then the Holder shall have the right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities,
cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been,
immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full
of this Warrant without regard to any limitations on exercise contained herein (the “Alternate Consideration”),
and the Holder shall no longer have the right to receive Warrant Shares upon exercise of this Warrant. The Company shall not effect
any such Fundamental Transaction unless prior to or simultaneously with the consummation thereof, any successor to the Company,
surviving entity or the corporation purchasing or otherwise acquiring such assets or other appropriate corporation or Person shall
assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with the foregoing provisions, the
Holder may be entitled to receive, and the other obligations under this Warrant (including without limitation this Section 9(e)
which shall apply to subsequent transactions of an analogous type to any Fundamental Transaction).

 

(f)             Notice
of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense shall
promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting
forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other
securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments
and showing in reasonable detail the facts upon which such adjustment is based. The Company shall promptly deliver a copy of each
such certificate to the Holder and to the Company’s transfer agent.

 

(g)           Notice
of Corporate Events. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution
of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or
warrants to subscribe for or purchase any capital stock of the Company, (ii) authorizes or approves, enters into any written agreement
contemplating, or solicits stockholder approval for, any Fundamental Transaction or (iii) authorizes the voluntary dissolution,
liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to
constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least five
(5) calendar days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to
participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any
defect therein shall not affect the validity of the corporate action required to be described in such notice.

 

(h)          Minimum
Percentage. For so long as any amounts remain outstanding under the Credit Facility (including any amendment, replacement or
refinancing thereof) to any Lender thereunder, if at any time the aggregate number of Warrant Shares into which the Warrants may
be exercised is less than the Minimum Percentage Amount, then the number of Warrant Shares into which the Warrants may be exercised
shall be adjusted upward to equal the Minimum Percentage Amount. For these purposes,

 

    	 	7	 

     

    

  

(i)          the
“Minimum Percentage Amount” shall be a number of shares of Common Stock equal to (A) seven and one-half percent
(7.5%) of the Common Stock Deemed Outstanding on the date of any such exercise, minus (B) the aggregate number of shares of Common
Stock previously issued from time to time as a result of any exercise of the Warrants;

 

(ii)         the
term “Common Stock Deemed Outstanding” shall mean, at any given time, (A) the number of shares of Common Stock
actually outstanding at that time, plus (B) the number of shares of Common Stock issuable upon exercise of Options actually outstanding
at such time, plus (C) the number of shares of Common Stock issuable upon conversion or exchange of Convertible Securities actually
outstanding at such time (treating as actually outstanding any Convertible Securities issuable upon exercise of Options actually
outstanding at such time), in each case regardless of whether the Options or Convertible Securities are actually issued at such
time; provided, that for purposes of determining the Common Stock Deemed Outstanding, all outstanding shares of Series A-1
Convertible Preferred Stock, par value $0.00001 per share, of the Company (and any other Convertible Securities with a conversion
rate determined by reference to a percentage of issued and outstanding Common Stock on the date of conversion) shall be considered
to have been converted simultaneously, and provided, further, that Common Stock Deemed Outstanding at any given time shall
not include shares owned or held by or for the account of the Company or any of its wholly-owned subsidiaries;

 

(iii)        the
term “Convertible Securities” shall mean any securities (directly or indirectly) convertible into or exchangeable
for Common Stock, but excluding Options; and

 

(iv)        the
term “Options” shall mean any warrants or other rights to subscribe for or purchase Common Stock or Convertible
Securities.

 

In the event more than one Warrant is outstanding at the time of
any adjustment pursuant to this Section 9(h), then the aggregate adjustment in the number of Warrant Shares shall be allocated
among the holders of the Warrants pro rata based on the proportion of Warrant Shares represented by each Warrant at the time of
the original issuance thereof or, in the case of subsequent partial transfers of Warrants after the initial issuance thereof, among
such Warrants pro rata based on the proportion of Warrant Shares represented by each Warrant at the time of such transfer or in
such other manner as the initial Holder thereof may direct in writing to the Company.

 

10.           Payment
of Exercise Price. The Holder shall pay the Exercise Price in immediately available funds; provided, however, the Holder
may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a “cashless exercise”, in which
event the Company shall issue to the Holder the number of Warrant Shares determined as follows:

 

    	 	8	 

     

    

  

X = Y [(A-B)/A]

 

where:

 

X = the number of Warrant Shares to be issued to the Holder.

 

Y = the total number of Warrant Shares with respect to
which this Warrant is being exercised.

 

A = the average of the Closing Sale Prices of the shares
of Common Stock (as reported by Bloomberg Financial Markets) for the five (5) Trading Days ending on the date immediately preceding
the Exercise Date.

 

B = the Exercise Price then in effect for the applicable
Warrant Shares at the time of such exercise.

 

For purposes of this Warrant, “Closing
Sale Price” means, for any security as of any date, the last trade price for such security on the principal securities
exchange or trading market for such security, as reported by Bloomberg Financial Markets, or, if such exchange or trading market
begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security
prior to 4:00 P.M., New York time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade
price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg
Financial Markets, or, if no last trade price is reported for such security by Bloomberg Financial Markets, the average of the
closing bid prices of any market makers for such security as reported on the Pink Open Market (formerly the “pink sheets”)
operated by OTC Markets Group Inc., or any successor market. If the Closing Sale Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value
as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value
of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value.
The Board of Directors’ determination shall be binding upon all parties absent demonstrable error. All such determinations
shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the
applicable calculation period.

 

For purposes of Rule 144 promulgated under
the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction
shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced,
on the date this Warrant was originally issued (provided that the U.S. Securities and Exchange Commission continues to take the
position that such treatment is proper at the time of such exercise).

 

    	 	9	 

     

    

  

11.           Beneficial
Ownership. Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise of any portion
of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the terms and conditions
of this Warrant and any such exercise shall be null and void and treated as if never made, to the extent that after giving effect
to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 9.99%
(the “Maximum Percentage”) of the number of shares of Common Stock outstanding immediately after giving effect
to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by
the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other
Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the
determination of such sentence is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
(A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution
Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including,
without limitation, any convertible notes or convertible preferred stock or warrants, including other Warrants) beneficially owned
by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained
in this Section 11. For purposes of this Section 11, beneficial ownership shall be calculated in accordance with
Section 13(d) of the Securities Exchange Act of 1934, as amended (the “1934 Act”). For purposes of this Warrant,
in determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without
exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the
Company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Current Reports on Form 8-K or other public
filing with the SEC, as the case may be, (y) a more recent public announcement by the Company or (3) any other written notice by
the Company or its transfer agent setting forth the number of shares of Common Stock outstanding (the “Reported Outstanding
Share Number”). If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding
shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i) notify the Holder in writing of
the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder's
beneficial ownership, as determined pursuant to this Section 11, to exceed the Maximum Percentage, the Holder must notify
the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice (the number of shares by which
such purchase is reduced, the “Reduction Shares”) and (ii) as soon as reasonably practicable, the Company shall
return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written
or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing or by electronic mail
to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock
shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the
event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other Attribution
Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares
of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by which the Holder's and the
other Attribution Parties' aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”)
shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer
the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the
Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. For purposes of clarity, the shares
of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially
owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability
to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph
with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 11 to the extent necessary to correct this
paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation
contained in this Section 11 or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant. For purposes
of this Section 11, “Attribution Parties” means, collectively, the following Persons and entities: (i)
any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the Subscription
Date, directly or indirectly managed or advised by the Holder's investment manager or any of its Affiliates or principals, (ii)
any direct or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting
as a group (within the meaning of the 1934 Act) together with the Holder or any of the foregoing and (iv) any other Persons whose
beneficial ownership of the Company's Common Stock would or could be aggregated with the Holder's and the other Attribution Parties
for purposes of Section 13(d) of the 1934 Act. For clarity, the purpose of the foregoing is to subject collectively the Holder
and all other Attribution Parties to the Maximum Percentage.

 

    	 	10	 

     

    

  

12.           No
Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of
any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the
next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any
such fractional shares.

 

13.           Notices.
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall
be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number specified in the Credit Facility prior to 5:30 P.M., New York time, on a Trading
Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile number specified in the Credit Facility on a day that is not a Trading Day or later than 5:30 P.M., New York time, on
any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service
specifying next business day delivery, or (iv) upon actual receipt by the party to whom such notice is required to be given, if
by hand delivery. The address and facsimile number of a party for such notices or communications shall be as set forth in the Credit
Facility unless changed by such party by two (2) Trading Days’ prior notice to the other party in accordance with this Section
12.

 

14.           Warrant
Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty (30) days’ notice to the Holder, the
Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation
resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the
Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be
a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice
of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last
address as shown on the Warrant Register.

 

    	 	11	 

     

    

  

15.          Representations
and Warranties of Holder. The Holder hereby represents and warrants that (i) the Holder meets the requirements of at least
one of the suitability standards for an “accredited investor” as that term is defined in Regulation D as promulgated
by the United States Securities and Exchange Commission; (ii) the Holder is acquiring the Warrant Shares solely for the Holder’s
account for investment purposes only and not with a view to or intent of resale or distribution thereof, in whole or in part, in
violation of the Securities Act, and the Holder has no present intention of selling, granting any participation in, or otherwise
distributing the same in violation of the Securities Act, without prejudice, however, to the Holder’s right at all times
to sell or otherwise dispose of all or any part of the Warrant Shares in compliance with applicable federal and state securities
laws and in compliance with any transfer restriction to which the applicable Warrant Shares may be subject at any time or from
time to time; and (iii) the Holder has such knowledge and experience in financial, tax, and business matters, and, in particular,
investments in securities, so as to enable it to utilize the information made available to it to evaluate the merits and risks
of an investment in the Company and the Warrant Shares and to make an informed investment decision with respect thereto.

 

16.           Miscellaneous.

 

(a)          No
Rights as a Stockholder. The Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled
to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained
in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any
of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any
reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive
notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant
Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this
Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant
or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

(b)          Successors
and Assigns. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant
may not be assigned by the Company without the written consent of the Holder. This Warrant shall be binding on and inure to the
benefit of the parties hereto and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant
shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of
action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors
and assigns.

 

    	 	12	 

     

    

  

(c)          Amendment
and Waiver. Except as otherwise provided herein, the provisions of the Warrant may be amended and the Company may take any
action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the
written consent of the Holder of this Warrant.

 

(d)          Future
Actions. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including,
without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the
taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the Company will (i) take all such action as may be necessary or
appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
of this Warrant, and (ii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body (including without limitation the NYSE MKT) having jurisdiction thereof as may be necessary to enable the
Company to perform its obligations under this Warrant.

 

(e)          Acceptance.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained
herein.

 

(f)         Governing
Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL
BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES
OF CONFLICTS OF LAW THEREOF. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS
SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH,
AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY
SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO
PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT
DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER SECTION 12 HEREOF AND
AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL
BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH PARTY HEREBY WAIVES ALL RIGHTS TO
A TRIAL BY JURY.

 

(g)          Headings.
The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect
any of the provisions hereof.

 

    	 	13	 

     

    

  

(h)         Severability.
In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the parties will
attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor,
and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

(i)           No
Effect Upon Lending Relationships. Anything herein to the contrary notwithstanding, nothing contained in this Warrant shall
affect, limit or impair the rights and remedies of the Administrative Agent, any of its or their affiliates, funding or financing
sources or any other lenders in their capacities as lenders to the Company or any of its subsidiaries (each a “Subject
Entity”) pursuant to any agreement under which the Company or any of its subsidiaries has or from time to time will have
borrowed money. Without limiting the generality of the foregoing, neither a Subject Entity nor any such other Person, in exercising
its rights as a lender or other creditor, including making its decision on whether to foreclose on any collateral security, shall
have any duty to consider (a) its status as a direct or indirect equityholder of the Company, (b) the interests of the Company
or any of its subsidiaries or (c) any duty it may have to any other direct or indirect equityholder of the Company, except as may
be required under the applicable loan documents or by commercial law applicable to creditors generally.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,

SIGNATURE PAGE FOLLOWS]

 

    	 	14	 

     

    

  

IN WITNESS WHEREOF, the
Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

	PARETEUM CORP.	 
	 	 	 
	By:	 	 
	 	Name:  	 
	 	Title:  	 

 

     

     

    

  

SCHEDULE 1

 

FORM OF EXERCISE NOTICE

 

(To be executed by the Holder to purchase
shares of

Common Stock under the foregoing Warrant)

 

Ladies and Gentlemen:

 

(1)           The
undersigned is the Holder of Warrant No. __________ (the “Warrant”) issued by Pareteum Corporation, a Delaware corporation
(the “Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth
in the Warrant.

 

(2)           The
undersigned hereby exercises its right to purchase __________ Warrant Shares pursuant to the Warrant.

 

(3)           The
Holder intends that payment of the Exercise Price shall be made as (check one):

 

 ̈       Cash
Exercise

 

 ̈      “Cashless
Exercise” under Section 10

 

(4)           If
the Holder has elected a Cash Exercise, the Holder shall pay the sum of $____________ in immediately available funds to the Company
in accordance with the terms of the Warrant.

 

(5)           Pursuant
to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the
Warrant.

 

Dated: ________________ ____, 20___

 

Name of Holder: ______________________

 

By: _________________________________

 

Name: _______________________________

 

Title: ________________________________

 

(Signature must conform in all respects to name
of Holder as specified on the face of the Warrant)

 

     

     

    

  

SCHEDULE 2

 

Pareteum Corporation

 

FORM OF ASSIGNMENT

 

[To be completed and signed only upon transfer
of Warrant]

 

FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers unto ________________________  (the “Transferee”) the right represented by
the within Warrant to purchase _____________  shares of Common Stock of Pareteum Corporation (the “Company”)
to which the within Warrant relates and appoints ____________________  attorney to transfer said right on the books
of the Company with full power of substitution in the premises.

 

Dated: ____________________ __, 20___

 

	 	 
	 	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)
	 	 
	 	 
	 	Address of Transferee
	 	 
	In the presence of:	 

 

_________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]